Pacira BioSciences, Inc.

PCRX

Pacira BioSciences, Inc.

PCRX

Insider Sentiment (TTM):

Last Purchase:2024-08-16Last Sale:2026-06-11Shares Purchased (TTM):0Shares Sold (TTM):80,607

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:60,258,218Shares Outstanding:40,461,000Institutional Ownership Pct.:148.93%

Earnings Market Reaction:

Filing Date:2026-08-04Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	206	144	159	148	300	284	277	246	247	184	153	99
Short Term Investments	45	58	80	99	145	210	208	208	157	142	125	136
Accounts Receivable Net Current	132	126	124	115	114	105	113	101	105	102	106	97
Inventory Net	135	150	153	158	148	134	125	112	103	97	104	97
Prepaid Expense And Other Assets Current	30	37	33	43	37	28	22	24	20	19	22	19
Assets Current	615	515	548	563	746	760	745	690	632	543	510	447
Property Plant And Equipment Net	130	136	141	147	155	164	167	167	169	172	174	176
Long Term Investments	-	-	-	-	-	-	0	0	0	0	2	0
Operating Lease Right Of Use Asset	45	39	42	44	47	49	49	54	56	59	61	63
Goodwill	20	20	20	20	20	22	0	0	163	163	163	163
Intangible Assets Net Excluding Goodwill	285	353	368	382	423	435	426	440	455	469	483	498
Deferred Income Tax Assets Net	125	122	124	120	128	129	130	134	135	141	144	152
Assets	1,244	1,209	1,265	1,298	1,537	1,587	1,554	1,522	1,647	1,583	1,574	1,534
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	18	14	15	18	30	23	19	19	19	9	16	17
Accrued Liabilities Current	93	85	96	80	71	80	80	76	65	67	64	60
Operating Lease Liability Current	10	10	10	10	10	9	9	9	9	9	9	9
Convertible Debt Current	-	-	-	-	202	202	202	201	0	9	9	9
Secured Debt Current	-	-	-	-	-	-	-	-	-	-	0	0
Debt Current	-	-	-	0	-	-	-	-	-	-	-	-
Long Term Debt Current	-	-	0	-	-	-	202	-	-	-	-	-
Liabilities Current	122	109	121	107	313	315	310	306	93	93	97	94
Convertible Debt Noncurrent	-	-	-	-	280	280	279	279	480	399	399	398
Secured Long Term Debt	-	-	-	-	98	101	104	107	110	112	115	118
Long Term Debt Noncurrent	363	368	372	377	-	-	384	-	-	-	-	-
Operating Lease Liability Noncurrent	39	34	36	39	41	44	45	48	50	52	55	57
Deferred Income Tax Liabilities Net	4	4	4	5	5	7	0	-	-	-	-	-
Other Liabilities Noncurrent	27	25	21	25	25	24	17	13	13	13	14	12
Liabilities	572	555	572	570	779	788	775	772	768	691	704	703
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Treasury Stock Common Value	-227	-227	-177	-126	-76	-25	-25	-25	-25	-	0	-
Additional Paid In Capital	1,087	1,074	1,065	1,050	1,036	1,024	1,009	996	983	990	977	963
Retained Earnings Accumulated Deficit	-192	-196	-199	-201	-206	-202	-206	-222	-79	-98	-107	-132
Accumulated Other Comprehensive Income Loss Net Of…	3	3	4	4	4	1	0	1	0	0	0	-0
Stockholders Equity	672	654	693	727	758	799	778	750	879	892	870	832
Liabilities And Stockholders Equity	1,244	1,209	1,265	1,298	1,537	1,587	1,554	1,522	1,647	1,583	1,574	1,534
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	5	5	5	5	5	5	5	5	5	5	5	5
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	250	250	250	250	250	250	250	250	250	250	250	250
Common Stock Shares Issued	49	48	48	48	48	47	47	47	47	47	46	46
Shares Outstanding	40	39	41	43	45	46	46	46	46	47	46	46
Treasury Stock Common Shares	9	9	7	5	3	1	1	1	1	-	0	-

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-8.40%	-12.40%	0.47%	-	-	-	-	-	-	-	-	-
2025	3.73%	-5.74%	-9.47%	18.32%	11.98%	-3.55%	11.71%	25.64%	-2.04%	-2.12%	9.43%	0.22%
2024	14.41%	7.92%	-24.44%	-27.38%	-25.64%	-10.49%	-4.30%	11.21%	38.77%	-4.89%	-2.88%	1.89%
2023	-	-	-	-	-	-	-7.81%	13.22%	9.08%	-3.53%	-11.68%	3.70%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	5.04	4.73	4.54	5.26	2.38	2.41	2.40	2.25	6.82	5.81	5.24	4.78
Quick Ratio	3.69	3.01	3.01	3.38	1.79	1.90	1.93	1.81	5.49	4.58	3.94	3.55
Working Capital	493.20M	406.17M	427.38M	455.67M	432.45M	445.23M	435.21M	383.57M	539.52M	449.67M	412.61M	353.59M
Leverage & Debt
Debt to Equity	0.85	0.85	0.82	0.78	1.03	0.99	1.00	1.03	0.87	0.77	0.81	0.85
Interest Coverage TTM	1.28	1.46	1.10	2.28	-5.60	-4.74	-4.43	-4.25	6.57	7.41	4.32	1.60
Debt Ratio	0.46	0.46	0.45	0.44	0.51	0.50	0.50	0.51	0.47	0.44	0.45	0.46
Efficiency & Turnover
Asset Turnover TTM	0.54	0.53	0.52	0.51	0.44	0.44	0.45	0.45	0.43	0.44	0.41	0.41
Days Sales Outstanding TTM	60.36	57.21	59.64	54.97	56.66	53.60	56.98	52.10	54.11	52.37	55.37	52.21
Receivables Turnover TTM	6.05	6.38	6.12	6.64	6.44	6.81	6.41	7.01	6.75	6.97	6.59	6.99
Per Share Metrics
Diluted EPS TTM	0.36	0.13	0.16	0.48	-2.80	-2.23	-2.15	-1.97	1.26	1.35	0.81	0.13
Free Cash Flow Per Share TTM	4.80	3.28	3.07	2.02	1.80	3.44	3.87	4.19	4.00	3.72	3.02	2.81
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	79.21%	79.34%	79.39%	79.17%	78.19%	77.61%	75.69%	74.25%	73.95%	73.04%	72.53%	70.12%
Operating Profit Margin TTM	2.66%	3.28%	2.64%	5.80%	-14.78%	-12.04%	-10.47%	-9.38%	13.43%	15.31%	13.04%	6.70%
Net Profit Margin TTM	1.96%	0.70%	0.97%	2.99%	-18.06%	-14.76%	-14.20%	-13.11%	9.25%	10.38%	6.24%	1.05%
Growth Metrics
Net Revenue Growth (1Y)	5.71%	4.57%	3.63%	3.55%	2.66%	3.50%	4.27%	3.99%	2.74%	1.47%	0.81%	1.78%
Net Income Growth (1Y)	-111.48%	-104.95%	-107.07%	-123.63%	-300.43%	-247.19%	-337.30%	-1,399.31%	-1,492.14%	-774.03%	163.72%	-66.56%
EPS Growth (1Y)	-113.23%	-105.67%	-107.33%	-124.75%	-303.58%	-247.91%	-337.18%	-1,407.25%	-1,489.55%	-766.06%	159.72%	-66.98%
Valuation Metrics
P/E TTM	68.39	177.97	163.97	52.94	-8.52	-11.09	-8.75	-7.65	20.77	19.28	37.17	203.93
P/B TTM	1.49	1.40	1.66	1.56	1.43	1.44	1.12	0.93	1.50	1.52	1.79	1.71
P/S TTM	1.34	1.24	1.59	1.58	1.54	1.64	1.24	1.00	1.92	2.00	2.32	2.14
Market Cap	1.00B	914.42M	1.15B	1.13B	1.09B	1.15B	871.26M	694.32M	1.32B	1.36B	1.56B	1.42B
Enterprise Value	1.16B	1.14B	1.37B	1.36B	1.37B	1.45B	1.38B	1.04B	1.66B	1.69B	1.93B	1.85B
Calculated Values
Free Cash Flow TTM	189.29M	132.71M	136.66M	88.75M	81.61M	159.40M	178.75M	193.53M	184.74M	173.19M	139.49M	130.25M
Net Debt	157.25M	223.35M	213.64M	229.13M	280.01M	299.77M	510.32M	341.39M	342.25M	336.28M	369.14M	425.46M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-11Sale

Owner: Riker, Lauren

Title: Senior Vice President, Finance

Shares: 6,115

Price/Share: $23.50

Value: $143,702.50

Shares Owned: 62,284

Relationship: Officer

Ownership: Direct

2026-06-04Sale

Owner: Williams, Kristen

Title: Chief Administrative Officer

Shares: 10,259

Price/Share: $22.27

Value: $228,467.93

Shares Owned: 167,062

Relationship: Officer

Ownership: Direct

2026-04-23Sale

Owner: Cross, Shawn

Title: Chief Financial Officer

Shares: 12,941

Price/Share: $25.16

Value: $325,595.56

Shares Owned: 105,341

Relationship: Officer

Ownership: Direct

2026-04-22Sale

Owner: Cross, Shawn

Title: Chief Financial Officer

Shares: 1,500

Price/Share: $25.01

Value: $37,515.00

Shares Owned: 105,341

Relationship: Officer

Ownership: Direct

2026-03-17Sale

Owner: Slonin, Jonathan

Title: Chief Medical Officer

Shares: 3,261

Price/Share: $22.82

Value: $74,416.02

Shares Owned: 223,640

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-11	Riker, Lauren	Officer	Senior Vice President, Finance	Direct	Sale	6,115	23.50	$143,702.50	62,284	4
2026-06-04	Williams, Kristen	Officer	Chief Administrative Officer	Direct	Sale	10,259	22.27	$228,467.93	167,062	4
2026-04-23	Cross, Shawn	Officer	Chief Financial Officer	Direct	Sale	12,941	25.16	$325,595.56	105,341	4
2026-04-22	Cross, Shawn	Officer	Chief Financial Officer	Direct	Sale	1,500	25.01	$37,515.00	105,341	4
2026-03-17	Slonin, Jonathan	Officer	Chief Medical Officer	Direct	Sale	3,261	22.82	$74,416.02	223,640	4
2026-03-17	Froimson, Mark	Director	-	Direct	Sale	500	21.81	$10,905.00	20,136	4
2026-02-02	Williams, Kristen	Officer	Chief Administrative Officer	Direct	Sale	13,137	20.53	$269,702.61	131,303	4
2026-02-02	Riker, Lauren	Officer	Senior Vice President, Finance	Direct	Sale	4,000	20.81	$83,240.00	52,313	4
2026-01-05	Riker, Lauren	Officer	Senior Vice President, Finance	Direct	Sale	1,416	24.24	$34,323.84	59,064	4
2025-12-10	Cross, Shawn	Officer	Chief Financial Officer	Direct	Sale	9,104	25.14	$228,874.56	56,250	4
2025-11-17	Slonin, Jonathan	Officer	Chief Medical Officer	Direct	Sale	3,960	24.09	$95,396.40	178,367	4
2025-11-10	Cross, Shawn	Officer	Chief Financial Officer	Direct	Sale	12,060	22.09	$266,405.40	56,250	4
2025-09-04	Ceesay, Abraham	Director	-	Direct	Sale	2,354	27.19	$64,005.26	9,039	4
2025-08-07	Bigal, Marcelo	Director	-	Direct	Sale	4,912	23.67	$116,267.04	11,393	4
2025-06-04	Riker, Lauren	Officer	Senior Vice President, Finance	Direct	Sale	5,578	26.21	$146,208.29	59,564	4
2025-06-04	Williams, Kristen	Officer	Chief Administrative Officer	Direct	Sale	14,376	26.24	$377,226.24	161,574	4
2025-01-06	Slonin, Jonathan	Officer	Chief Medical Officer	Direct	Sale	879	18.40	$16,173.60	93,444	4
2024-12-13	Gaugler, Daryl	Officer	Chief Operating Officer	Direct	Sale	500	19.76	$9,880.00	115,200	4
2024-09-13	Gaugler, Daryl	Officer	Chief Operating Officer	Direct	Sale	500	12.86	$6,430.00	115,700	4
2024-08-16	Bigal, Marcelo	Director	-	Direct	Purchase	1,512	13.25	$20,034.00	10,142	4
2024-08-16	Brege, Laura	Director	-	Direct	Purchase	1,000	12.81	$12,810.00	17,552	4
2024-08-14	Yang, Michael J.	Director	-	Direct	Purchase	2,000	12.90	$25,800.00	7,230	4
2024-08-12	Froimson, Mark	Director	-	Direct	Purchase	1,400	11.58	$16,212.00	14,473	4
2024-08-12	Bigal, Marcelo	Director	-	Direct	Purchase	3,400	12.01	$40,834.00	8,630	4/A
2024-08-12	Lee, Frank D.	Director,Officer	Chief Executive Officer	Direct	Purchase	8,264	12.10	$99,994.40	107,784	4
2024-08-02	Slonin, Jonathan	Officer	Chief Medical Officer	Direct	Sale	945	20.05	$18,947.25	94,307	4
2024-07-02	Slonin, Jonathan	Officer	Chief Medical Officer	Direct	Sale	2,836	28.25	$80,117.00	95,557	4
2024-06-13	Gaugler, Daryl	Officer	Chief Operating Officer	Direct	Sale	1,000	28.38	$28,380.00	116,040	4
2024-06-13	Williams, Kristen	Officer	Chief Administrative Officer	Direct	Sale	7,452	28.38	$211,487.76	102,912	4
2024-06-13	Hastings, Paul J	Director	-	Direct	Sale	880	28.38	$24,974.40	12,724	4
2024-06-12	Riker, Lauren	Officer	Senior Vice President, Finance	Direct	Sale	3,970	28.72	$114,018.40	38,075	4
2024-06-11	Slonin, Jonathan	Officer	Chief Medical Officer	Direct	Sale	5,012	28.57	$143,192.84	44,569	4
2024-03-08	Pace, Gary W	Director	-	Direct	Sale	90,000	30.60	$2,754,000.00	22,127	4
2023-08-02	Winston, Roy	Officer	Chief Medical Officer	Direct	Sale	509	34.88	$17,753.92	52,440	4
2023-07-05	Riker, Lauren Bullaro	Officer	Senior Vice President, Finance	Direct	Sale	643	38.91	$25,019.13	22,687	4
2023-06-14	Riker, Lauren Bullaro	Officer	Senior Vice President, Finance	Direct	Sale	6,366	38.33	$244,008.78	22,687	4
2023-06-14	Williams, Kristen Marie	Officer	Chief Administrative Officer	Direct	Sale	6,467	37.03	$239,473.01	25,375	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

148.93%

Inst. Shares: 60,258,218

Shares Outstanding: 40,461,000

2025-12-31

141.55%

Inst. Shares: 63,081,349

Shares Outstanding: 44,566,000

2025-09-30

141.66%

Inst. Shares: 62,384,515

Shares Outstanding: 44,038,000

2025-06-30

147.40%

Inst. Shares: 67,005,996

Shares Outstanding: 45,459,000

2025-03-31

106.01%

Inst. Shares: 49,055,123

Shares Outstanding: 46,275,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	60,258,218	40,461,000	148.93%
2025-12-31	63,081,349	44,566,000	141.55%
2025-09-30	62,384,515	44,038,000	141.66%
2025-06-30	67,005,996	45,459,000	147.40%
2025-03-31	49,055,123	46,275,000	106.01%
2024-12-31	48,613,260	46,245,000	105.12%
2024-09-30	49,908,321	46,134,000	108.18%
2024-06-30	50,287,343	46,174,000	108.91%
2024-03-31	45,897,483	46,499,000	98.71%
2023-12-31	45,162,876	46,222,000	97.71%
2023-09-30	43,888,956	46,416,000	94.56%
2023-06-30	43,320,189	46,088,000	93.99%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Pacira BioSciences, Inc. (PCRX) — SEC Financial Statements & Analysis

Pacira BioSciences, Inc. (PCRX) is a pharmaceutical preparations company, incorporated in DE. Pacira BioSciences, Inc. trades on Nasdaq as: PCRX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Pacira BioSciences, Inc. reported a 5.71% year-over-year revenue growth, a Gross Profit Margin of 79.21% (TTM), a Debt-to-Equity ratio of 0.85x, a Price-to-Sales (P/S) ratio of 1.34x (TTM), a Price-to-Book (P/B) ratio of 1.49x (TTM), at a market cap of $1.00B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 5.71%
Gross Profit Margin TTM: 79.21%
Debt To Equity: 0.85x
P/S TTM: 1.34x
P/B TTM: 1.49x
Market Cap: $1.00B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Pacira BioSciences, Inc. in?

Pacira BioSciences, Inc. (PCRX) operates in the Pharmaceutical Preparations industry.

What is PCRX's market cap?

Pacira BioSciences, Inc. (PCRX) has a market capitalization of $1.00B as of 2026-06-30.

What is PCRX's P/E ratio?

Pacira BioSciences, Inc. (PCRX)'s trailing twelve month P/E ratio is 68.39x as of 2026-06-30.

What exchange does PCRX trade on?

Pacira BioSciences, Inc. (PCRX) trades on the Nasdaq.

Where is Pacira BioSciences, Inc. incorporated?

Pacira BioSciences, Inc. is incorporated in DE.